Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · operational-macro

FDA Clears MeMed BV Assay to Distinguish Bacterial and Viral Infections

7 November 2026 · By · Wire by Fusion42

Published

7 November 2026

Topic

operational-macro

◆ Sectors

Diagnostics

◆ Geography

United States

◆ Source

Read at idse.net →

◆ Verified

Fusion42 · 7 November 2026 · Fusion42 review

The FDA has cleared the MeMed BV Assay, a rapid blood test that distinguishes between bacterial and viral infections in patients as young as 90 days old, providing results in about 15 minutes to aid clinical treatment decisions.

This Wire brief sits within Fusion42's coverage of Diagnostics, and 9 sources have reported it between 3 Nov 2026 and 12 Nov 2026.

◆ ◆ The Wire takeaway

You can now build faster testing tools that assist doctors with antibiotic decisions in minutes, not days. The FDA’s clearance lowers the barrier for deploying rapid infection diagnostics in clinical settings.

◆ Coverage

9 sources · first reported 3 Nov 2026 · latest 12 Nov 2026

◆ Related on Wire

◆ Topics

Diagnosticsfda-clearancediagnosticsrapid-testingbacterial-infectionsviral-infections